CELLINK AB and seqWell, Inc. have entered into an agreement in which CELLINK will commercialize seqWell’s products, including the upcoming plexWell Single-cell Rapid Kit for plate-based single-cell RNA sequencing, to a wider audience outside the United States. The agreement encompasses seqWell’s full line of plexWell library preparation kits for a wide range of multiplexed NGS applications.
Releasing in February, plexWell Single-cell Rapid Kit will offer a comprehensive library prep solution for users of CELLINK’s single-cell sorting and reagent dispensing platforms. It will streamline the preparation of NGS libraries for the quick and easy full-length cDNA sequencing of hundreds or thousands of cells, enabling single-cell analysis with market-leading precision.
In addition to the distribution agreement, the companies will also collaborate on additional integrated solutions that address the need for multiplexing of complex genomic assays, building on their complementary platform strengths.
“This collaboration presents an exciting step forward for CELLINK’s Bioscience business area. Working with seqWell, we are now able to offer an entire workflow for single-cell RNA sequencing and NGS library preparation,” says Julian Riba, CSO of cytena, a CELLINK company. “There has been tremendous progress in the field of single-cell analysis, and we now want to make this available to all researchers. seqWell’s robust chemistry and streamlined protocols fit well with our strategy of automating and democratizing single-cell omics.
“We are excited to work with the CELLINK team and broaden the reach of our powerful omics tools to a larger number of scientists, especially in single-cell applications,” says Joseph Mellor, seqWell CEO. “The complementary portfolio offered by our companies will provide researchers with a more integrated set of solutions that address our customers’ needs.”
For more information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
Email: [email protected] Email: [email protected]
This information was submitted for publication through the agency of the contact persons set out above on February 8, 2021, 14:00 CET.
Founded in 2016, CELLINK is the leading bio-convergence company in the world, providing technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multi-omics, cell line development and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine.
Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm under CLNK B.